Literature DB >> 11556839

Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.

F Wärnberg1, H Nordgren, L Bergkvist, L Holmberg.   

Abstract

Ductal breast carcinoma in situ (DCIS) is regarded as a precursor to invasive breast cancer. The progression from in situ to invasive cancer is however little understood. We compared some tumour markers in invasive and in situ breast carcinomas trying to find steps in this progression. We designed a semi-experimental setting and compared histopathological grading and tumour marker expression in pure DCIS (n = 194), small invasive lesions (n = 127) and lesions with both an invasive and in situ component (n = 305). Grading was done according to the Elston-Ellis and EORTC classification systems, respectively. Immunohistochemical staining was conducted for p53, c-erbB-2, Ki-67, ER, PR, bcl-2 and angiogenesis. All markers correlated with grade rather than with invasiveness. No marker was clearly associated with the progression from in situ to invasiveness. The expression of tumour markers was almost identical in the 2 components of mixed lesions. DCIS as a group showed a more 'malignant picture' than invasive cancer according to the markers, probably, due to a higher proportion of poorly differentiated lesions. The step between in situ and invasive cancer seems to occur independently of tumour grade. The results suggest that well-differentiated DCIS progress to well-differentiated invasive cancer and poorly differentiated DCIS progress to poorly differentiated invasive cancer. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556839      PMCID: PMC2375068          DOI: 10.1054/bjoc.2001.1995

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  Ductal carcinoma in situ.

Authors:  S M Swain
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

2.  Breast conserving surgery in the management of in situ breast carcinoma.

Authors:  M D Graham; S Lakhani; J C Gazet
Journal:  Eur J Surg Oncol       Date:  1991-06       Impact factor: 4.424

3.  New aspects of the natural history of in situ and invasive carcinoma in the female breast. Results from autopsy investigations.

Authors:  J Andersen; M Nielsen; L Christensen
Journal:  Verh Dtsch Ges Pathol       Date:  1985

4.  Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.

Authors:  H Buerger; F Otterbach; R Simon; C Poremba; R Diallo; T Decker; L Riethdorf; C Brinkschmidt; B Dockhorn-Dworniczak; W Boecker
Journal:  J Pathol       Date:  1999-03       Impact factor: 7.996

5.  The clinical significance of pre-invasive breast carcinoma.

Authors:  P P Rosen; D W Braun; D E Kinne
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

6.  Alternatives in the surgical management of in situ breast cancer. A meta-analysis of outcome.

Authors:  S J Bradley; D W Weaver; D L Bouwman
Journal:  Am Surg       Date:  1990-07       Impact factor: 0.688

7.  Clinically occult ductal carcinoma in situ detected with mammography: analysis of 100 cases with radiologic-pathologic correlation.

Authors:  P C Stomper; J L Connolly; J E Meyer; J R Harris
Journal:  Radiology       Date:  1989-07       Impact factor: 11.105

8.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Authors:  D C Allred; G M Clark; R Molina; A K Tandon; S J Schnitt; K W Gilchrist; C K Osborne; D C Tormey; W L McGuire
Journal:  Hum Pathol       Date:  1992-09       Impact factor: 3.466

9.  c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.

Authors:  J E Somerville; L A Clarke; J D Biggart
Journal:  J Clin Pathol       Date:  1992-01       Impact factor: 3.411

10.  Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

Authors:  P Price; H D Sinnett; B Gusterson; G Walsh; R P A'Hern; J A McKinna
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  26 in total

1.  Gene expression profiles of human breast cancer progression.

Authors:  Xiao-Jun Ma; Ranelle Salunga; J Todd Tuggle; Justin Gaudet; Edward Enright; Philip McQuary; Terry Payette; Maria Pistone; Kimberly Stecker; Brian M Zhang; Yi-Xiong Zhou; Heike Varnholt; Barbara Smith; Michelle Gadd; Erica Chatfield; Jessica Kessler; Thomas M Baer; Mark G Erlander; Dennis C Sgroi
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-24       Impact factor: 11.205

2.  Ductal carcinoma in situ: a rose by any other name.

Authors:  D Lawrence Wickerham; Thomas B Julian
Journal:  J Natl Cancer Inst       Date:  2013-09-25       Impact factor: 13.506

3.  [Prognostic factors in ductal carcinoma in situ].

Authors:  A Lebeau
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

4.  Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.

Authors:  H Wong; S Lau; R Leung; J Chiu; P Cheung; T T Wong; R Liang; R J Epstein; T Yau
Journal:  Med Oncol       Date:  2011-10-08       Impact factor: 3.064

5.  Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Authors:  Edgar S Díaz-Cruz; Priscilla A Furth
Journal:  Cancer Res       Date:  2010-05-15       Impact factor: 12.701

6.  Role of Plasma D-Dimer Levels in Breast Cancer Patients and Its Correlation with Clinical and Histopathological Stage.

Authors:  Harish S; Raxith Sringeri R; Sarath Chandra P
Journal:  Indian J Surg Oncol       Date:  2017-08-08

7.  Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count.

Authors:  Ossama Tawfik; Bruce F Kimler; Marilyn Davis; Christopher Stasik; Sue-Min Lai; Matthew S Mayo; Fang Fan; John K Donahue; Ivan Damjanov; Patricia Thomas; Carol Connor; William R Jewell; Holly Smith; Carol J Fabian
Journal:  Virchows Arch       Date:  2007-04-26       Impact factor: 4.064

8.  Angiogenesis in the progression of breast ductal proliferations.

Authors:  Philip M Carpenter; Wen-Pin Chen; Aaron Mendez; Christine E McLaren; Min-Ying Su
Journal:  Int J Surg Pathol       Date:  2009-04-29       Impact factor: 1.271

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.